Drozitumab ELISA Kit (GXEL00010)

Drozitumab ELISA Kit

The Drozitumab ELISA Kit (SKU: GXEL00010) is a quantitative sandwich ELISA designed for the accurate quantitative detection of Drozitumab across Plasma, Serum. With a working range of 0.31-5 μg/mL and a sensitivity of 0.156 μg/ml, the kit combines a simple protocol with dependable colorimetric read-out for confident quantification.

Drozitumab is a human monoclonal antibody directed against tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), a member of tumor necrosis factor related apoptosis-inducing ligand (TRAIL). It was developed by Genentech as a drug for the treatment of cancers. This drug has been investigating in various trials for treating cancers including chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. The efficacy and selectivity of drozitumab in rhabdomyosarcoma (RMS) has been evaluated in preclinical models. And results showed that drozitumab is effective, in vitro, against the majority of RMS cell lines that express caspase-8 and, in vivo, may provide long-term control of RMS. In preclinical glioblastoma models, drozitumab has been found to induce apoptosis and colony formation in several glioblastoma cell lines combined with BV6 (combination index<0.1). A study about triple-negative breast cancer reported that drozitumab could induce apoptosis in mesenchymal TNBC cell lines but not in cell lines from other breast cancer subtypes. The previous study about the treatment of pancreatic ductal adenocarcinoma has revealed that drozitumab could selectively eliminate CSCs, resulting in tumor growth inhibition and even regression of pancreatic tumors.

Backed by Assay Genie quality control and technical support, this Drozitumab ELISA Kit is an ideal tool for laboratories studying Drozitumab. Order the Drozitumab ELISA Kit from Assay Genie for dependable performance.